BioMarin Q4 top line up 1%

BioMarin Pharmaceutical (NASDAQ:BMRN) Q4 results ($M): Revenues: 353.2 (-1.4%).

Key product sales: Vimizim: 114.0 (flat); Kuvan: 112.2 (+4.5%); Naglazyme: 76.7 (-18.2%); Aldurazyme: 17.4 (-38.5%); Brineura: 12.2 (+134.6%); Palynziq: 8.1.

Net loss: (3.7) (+92.8%); non-GAAP net income: (10.8)(-307.7%); loss/share: (0.03) (+90.0%).

2019 guidance: Revenues: $1,680M – 1,750M; Vimizim: $530M – 570M; Kuvan: $420M – 460M; Naglazyme: $350M – 380M; Palynziq: $70 – 100M; Brineura: $55M – 76M; net income: $130M – 170M; net loss: ($85M – 45M).

Previously: BioMarin Pharmaceutical beats by $0.18, misses on revenue(Feb. 21)

https://seekingalpha.com/news/3435920-biomarin-q4-top-line-1-percent